- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Infinity Pharmaceuticals Inc.
- Takeda Oncology
- GlaxoSmithKline PLC
- Exelixis Inc.
- Genentech Inc.
- Chugai Pharmaceutical Co. Ltd.
- Antisoma PLC
- Johnson & Johnson
- Alza Corp.
- TransForm Pharmaceuticals Inc.
- Dynogen Pharmaceuticals Inc.
- Vertex Pharmaceuticals Inc.
- Predix Pharmaceuticals Holdings Inc.
- Harvard University
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Abbott Laboratories Inc.
- Novartis Institutes for BioMedical Research Inc.
- Myriad Genetics Inc.
- Curis Inc.
- Bristol-Myers Squibb Co.
- Bayer AG
- Novartis buys Pfizer's Enablex for CHF310.5mm
- Ciba-Geigy and Sandoz merged in $27 billion deal
- GSK, Exelixis co-develop, -promote therapeutics; terminated
- Roche licenses Antisoma's oncology compounds
- J&J agrees to acquire Alza for stock
- Alza and Transform build optimization platform
- Dynogen applies predictive model for J&JPR&D
- Novartis, Vertex in kinase protein deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.